Proven Efficacy of a Biolimus A9™ Drug
Biolimus A9™ (BA9™)
Low Late Loss
- Lower level of late loss achieved in the LEADERS trial with the Biolimus A9™ eluting stent at 9 months compared to Sirolimus eluting stent6
- In Stent late loss in LEADERS = 0.13mm6
Highest lipophilicity of the common limus drugs8
- Minimizes systematic exposure and reduces the circulating drug into the bloodstream
- Due to high lipophilicity, the drug is rapidly absorbed by tissue
CAUTION: Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.
Biosensors’ Interventional Cardiology products, including BioMatrix™, Gazelle™, S-Stent™ and Powerline™, are currently not available for sale in the United States.
* Data on file - molecular weight <10kDa
6.
Windecker S. et al., Biolimus-eluting stent with biodegradable polymer versus Sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non inferiority trial; The Lancet 2008; 372 No. 9644: 1163-1173. Data applicable to the stent used in the LEADERS trial
7.
Windecker S et al., NEJM 2005; Morice M. -C. et al., JAMA 2006; Serruys P.W. et al., Eurointervention 2006; Stone G.W. et al., JAMA 2008; Costa M. et al., Am J Card 2006; Chevalier B. et al., Eurointervention 2006; Ostojic M. et al., Eurointervention 2008; Stone G.W . er al., NEJM 2004; Krukoff M.W., JACC 2008; Verheye S. et al., ACC/SCAI 2008
8.
Data on file
How it works
Watch the working principle of our abluminal biodegradable polymer DES
